PharmaLectures.com

Courses › Regulatory affairs by region › Asia Pacific: China NMPA for foreign companies, registration, DMF and the 2019 reform

Asia Pacific: China NMPA for foreign companies, registration, DMF and the 2019 reform

Send China dossiers that clear technical review without a deficiency notice.

  • 12 audio modulesthree lengths each
  • 2 h to 10 hbriefing to expanded
  • Workbook, transcript, certificateand a recorded quiz per module
  • RA, QA, BDwho it is written for

Why this training matters

The finished product application reaches the Center for Drug Evaluation, but your ingredient supplier's Drug Master File is not linked. A deficiency notice arrives, the China team goes quiet, and the launch date moves. Headquarters asks why, and nobody has a straight answer.

What changes after this course

Your team files in the right category, links the Drug Master File and answers agency queries in the reviewer's own terms. You hold a certificate for each learner and a training record for each person, backed by a recorded multiple-choice questionnaire per module.

Watch the pitch

3:43 on how an audio course is bought, listened to and recorded. Full screen, one click.

Watch the pitch3:43, full screen, one click

What this course gives your people

A filing lands on the right desk at the National Medical Products Administration the first time. Your regulatory team reads the 2019 Drug Administration Law against a legacy dossier and sees the conflict before the Center for Drug Evaluation does. The marketing authorization holder contract gets checked against the law's duties before anyone signs it.

The category question gets answered in the meeting, not after a week of emails. Your team picks the registration category, lays out toxicology reports to Chinese technical guidelines and builds clinical data to China Good Clinical Practice. They also know when the 2018 overseas-data guidance carries your foreign results and when Chinese patient data is still needed.

Your ingredient supplier files its Drug Master File with the Center for Drug Evaluation, and your team links it to the finished product without exposing the supplier's process. Variations go out in the right lane: approval, filing or annual report. The recall that follows a wrongly filed change stops being a risk you carry.

When notice of a pre-approval inspection arrives, your quality people already know which Good Manufacturing Practice records come out first and how to answer questions about batch records. Your device team classifies the product, appoints the legal agent in China and files the right paperwork for Class III devices on the first attempt.

Who needs this training

  • Regulatory Affairs Manager

    The Center for Drug Evaluation sends a deficiency notice and the dossier goes back for reformatting. After this course you file to the Chinese technical guidelines and answer the notice in the reviewer's own terms.

  • Quality Assurance Lead

    An inspector asks to see batch records from a foreign site. You know what Chinese Good Manufacturing Practice inspectors ask for and have the records ordered the way they expect.

  • Business Development Director

    A partner asks when the product could launch in China. You read the registration category, the Drug Master File link and the 2019 law, and give a date you can defend.

  • Project Manager, China Market Entry

    The launch stalls because the Drug Master File is not linked. You line up the holder appointment and the ingredient filing so the product application is not held.

Roles: Business development and export sales, Regulatory affairs, Quality assurance and Qualified Person

Businesses: every kind of pharma company

Countries: India, China, Türkiye, Korea, Japan, Taiwan, Egypt, Gulf and MENA, Brazil and Latin America, Pakistan, Bangladesh and Vietnam, United States, Europe

Selling into: Asia Pacific

Courses are in English. Other languages on request.

After this course your people can

  1. Draft a marketing authorization holder contract that states the duties the 2019 Drug Administration Law places on the holder.
  2. Route each submission and query to the correct unit of the National Medical Products Administration.
  3. Lay out a pre-clinical toxicology report to the Chinese technical guidelines before the Center for Drug Evaluation reviews it.
  4. Link a confidential Drug Master File to a finished drug product application.
  5. Classify a medical device and state the registration route that applies to a foreign entity.
  6. Prepare a foreign manufacturing site for a Good Manufacturing Practice pre-approval inspection.
  7. Sort a post-approval change into approval, filing or annual report before it ships.

What the company gets

  • Your regulatory team stops sending dossiers back for reformatting, so submission dates in China hold.
  • Launch plans rest on the 2019 Drug Administration Law as your own staff applies it, not on guesses from head office.
  • Inspectors get straight answers about batch records and Good Manufacturing Practice, because the people in the room know what they ask.
  • Drug Master Files arrive linked the first time, so the product review is not held waiting for an ingredient filing.
  • Each learner holds a certificate and a training record you can show an auditor.

The evidence: questionnaire, training record, certificate

EU GMP Chapter 2, section 2.11, and 21 CFR 211.25 both ask for training that is documented and shown to work. This is what each learner leaves behind.

A recorded questionnaire per module

Every one of the 12 modules ends with a multiple-choice questionnaire. The result is recorded per person with a timestamp, whichever of the three lengths the person listened to.

A per-person training record

The export lists each learner, each module, the result and the date, which is the training record EU GMP Chapter 2 and 21 CFR 211.25 ask you to keep and the first thing an inspector asks for.

A certificate per learner

Name, company, course, hours, the guideline version taught and the date. It documents in-company training; it is not a professional qualification or an accreditation.

Your pass mark, your rule

There is no fixed pass mark. Your quality or human-resources manager decides what counts as passed and when a module is retaken, exactly as your training procedure says.

Delivered within 72 hours of payment, with the workbook, the full transcript and a source for every fact in the audio.

How long it takes, by who is listening

Nobody spends a day in a classroom. Every module exists in three lengths; a person takes the length their role needs, and every length ends with the same recorded questionnaire, so the training record is complete either way.

Briefing2 h10 min a module, for executives, sales and anyone who must know the rules, not run them
Standard5 h25 min a module, for regulatory, quality and business-development staff
Expanded10 h50 min a module, for technical staff who run the procedure day to day
Who takes this courseLengthTotal time
Business development and export salesBriefing2 h
Regulatory affairsStandard5 h
Quality assurance and Qualified PersonStandard5 h

Course outline: 12 modules

12 modules. Under each title are the three things the listener can do afterwards; the audio itself runs 10 to 50 minutes depending on the length chosen.

  1. 1Find the right office at the National Medical Products Administration

    • How to send a filing to the right National Medical Products Administration unit on the first try.
    • The split between review, inspection and post-market bodies that tells you who owns each question.
    • What to do when the local team reports a query and nobody can say which office sent it.
  2. 2Apply the 2019 Drug Administration Law to legacy dossiers and new filings

    • What to do when a dossier written before 2019 conflicts with the revised Drug Administration Law.
    • The new duties on the marketing authorization holder that surprise head office after approval.
    • How to frame a submission so your legal team and your China agent read the same law the same way.
  3. 3Set up a Marketing Authorization Holder system that holds up under audit

    • Why the choice of local legal person decides who answers to the agency when something goes wrong.
    • How to test a candidate holder against the duties the 2019 law puts on it before you sign.
    • The clauses that keep quality responsibility clear between you and your contract manufacturer.
  4. 4Pick the drug registration category and pathway that fits your product

    • How to decide between an innovative, improved or generic registration category without a rework.
    • The misclassification that sends a biological product down a chemical drug data path.
    • When the traditional Chinese medicine route fits your product and when it does not.
  5. 5Format pre-clinical data the way Chinese technical guidelines expect

    • How to lay out toxicology reports so a Chinese reviewer finds each study where expected.
    • The Good Laboratory Practice evidence that reviewers look for in a foreign pre-clinical package.
    • What to do when a study your home agency never asked for turns up in the Chinese guideline.
  6. 6Format clinical trial data to meet China Good Clinical Practice

    • How to design a trial that meets China Good Clinical Practice before the first patient is enrolled.
    • When the 2018 guidance on overseas clinical data lets your foreign results stand and when it does not.
    • The data presentation the Center for Drug Evaluation expects in a clinical trial submission.
  7. 7Link your Drug Master File to the product applications that depend on it

    • How to file a Drug Master File so the ingredient maker's secrets stay out of your product dossier.
    • The steps that link an active ingredient registration to the finished product application.
    • What happens to your product application when the linked registration is missing or unapproved.
  8. 8Pass the Center for Drug Evaluation technical review with fewer queries

    • The checks the Center for Drug Evaluation runs first, so you fix them before upload.
    • How to answer a deficiency notice in the terms the reviewer uses, inside the deadline.
    • Why the format of your electronic submission can stall a review before any scientist reads it.
  9. 9Submit variations in the right category and avoid product recalls

    • How to tell a change that needs approval from one that needs filing or only an annual report.
    • What to do when an unreported adverse event puts your marketing authorization holder at risk.
    • The change that looks small, ships in the wrong category and ends in a product recall.
  10. 10Classify your medical device and register it as a foreign entity

    • How to classify a device before you appoint the China legal agent who files it.
    • The registration steps that differ for imported Class II and Class III devices.
    • Why a wrong class sends the whole submission back to the start.
  11. 11Prepare your site to pass a Chinese Good Manufacturing Practice inspection

    • How to ready a foreign site for a pre-approval inspection before the notice arrives.
    • The Good Manufacturing Practice records Chinese inspectors ask to see and how to have them to hand.
    • What to do when an inspector questions how your batch records are kept.
  12. 12Adapt your dossiers to real-world data rules and guideline updates

    • How to use real-world data in a submission under the current Chinese rules.
    • Why a standing watch on guideline updates keeps a legacy product on the market.
    • What to change in your dossier templates as the agency moves further toward electronic submission.
The founders

One of us was inspected. The other one pays for the training.

Every claim below is sourced on the about page: the medicines register, the Lithuanian Pharmaceutical Union board list, the university directory.

Justina Krukonytė-Racz

Justina Krukonytė-Racz

Co-founder. Licensed pharmacist.

GDPResponsible PersonWarehouse & logistics

Licensed pharmacist. Responsible Person at Tamro (PHOENIX group), where she led the GDP set-up of the distribution centre.

The Responsible Person is the named person the regulator holds accountable for every pallet that leaves the building.

She writes the modules around the procedures a GDP inspection checks. Board member of Lithuanian Pharmaceutical Union.

Listed in the Lithuanian medicines register as Pharmacist.

Prof. Ben Racz

Prof. Ben Racz

Co-founder. Builds the platform and is responsible for delivery, records and pricing.

Platform & deliveryQuantitative researchCarnegie Mellon

He was Professor of the Practice at the College of Engineering at Carnegie Mellon University, where he taught Advanced Quantitative Finance and Algorithmic Trading to MSc students.

He is the founder and Managing Director of Algorithmic Sciences, a scientific research and consulting firm. Earlier he co-founded a data-driven growth consultancy, a data-science based wholesale trading company and an information security firm.

More about Ben at benracz.com

Questions about this course

Is there a certificate?

Yes. Every learner who finishes the course receives a certificate in their own name, and every module ends with a recorded multiple-choice questionnaire, so the certificate sits on top of a per-person training record. The certificate documents in-company training; it is not a professional qualification or an accreditation, and your quality or human-resources manager sets the pass mark and decides when a module is retaken.

How long does the course take?

12 modules, each in three lengths: a 10-minute briefing, a 25-minute standard run and a 50-minute expanded walk-through. The whole course takes 2 h in the briefing length and 10 h in the expanded length. People take the length their role needs, and every length ends with the same recorded questionnaire, so the training record is complete either way.

Who should take this course?

It is written for RA, QA, BD. Owners, managers and sales staff hear the briefing length, regulatory, quality and business-development staff take the standard run, and the people who run the procedure every day get the expanded version. One licence covers one named person on this course for a year, so the same title can be rolled out across a whole team at once.

Is this training accepted as a GMP training record by an auditor?

EU GMP Chapter 2 and 21 CFR 211.25 require documented, effective training, and that is what the course produces: a recorded multiple-choice result per module and per person, a certificate per learner and a transcript of what was taught. No provider can promise acceptance by a specific inspector; the record is built to answer what inspectors ask for, and your quality manager decides the pass mark.

How is it delivered and how fast?

The course arrives as audio files with a companion workbook, a full transcript and the questionnaire per module, within 72 hours of your payment arriving. You host the files on your own system or share them as you like; there is no platform to log into and no learner management system to set up. The free sample module arrives on request, before any purchase.

What does it cost per learner?

The list price is 9 euros per module, per learner, per year, so this course is 108 euros for one person for twelve months. The price per learner falls as more people take the same course: 10 learners pay 10 percent less and the discount keeps growing to 50 percent at 1000 learners. Type a number on the price panel and the yearly total appears.

Get this course for your team

One licence is one person on this course for a year. All three lengths, the workbook, the certificate and the training record are included in every purchase. Pick how many people, add it to the cart, and you have an invoice in your inbox.

Free sample module

Hear one full module before you spend a cent. Send your company and the role you want trained, and a complete sample module comes back with its workbook and transcript.

Connect on WhatsApp

or email [email protected], or ask for a written quote for your team